Resolution of the IV International Menopause Expert Forum

Authors

DOI:

https://doi.org/10.18370/2309-4117.2023.69.2-6

Keywords:

resolution, International Menopause Expert Forum, menopausal hormone therapy, perimenopause, combined oral contraceptives

Abstract

The IV International Menopause Expert Forum took place on November 24, 2022. The expert panel included leading endocrine gynaecologists from Armenia, Azerbaijan, Georgia, Kazakhstan, Moldova, Ukraine, Uzbekistan, and Ukraine. The experts discussed interdisciplinary cooperation in the management of menopausal women, the eligibility criteria for menopausal hormone therapy (MHT) and their implementation in routine clinical practice and developed an algorithm for switching from combined oral contraceptives (COCs) to MHT. Due to the lack of awareness and access to information and services related to menopause, interdisciplinary cooperation aimed at early detection of symptoms and diagnosis of menopausal disorders for timely treatment is paramount. The Forum participants highlighted the need for a series of steps to ensure comprehensive management of menopausal women. The Expert Forum reviewed the 2022 «Eligibility criteria for menopausal hormone therapy: a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions». The developed criteria for the acceptability of different MHT types for women with comorbidities is an essential step in expanding the possibilities for the use of MHT by physicians of various therapeutic areas. Moreover, the criteria help to identify populations for whom certain types of MHT are associated with risks. Importantly, the discussed eligibility criteria are not yet universally accepted. Therefore, in routine clinical practice, when deciding whether to prescribe a particular type of MHT, it is vital to take an individual approach and assess the benefit/risk balance, considering the patient’s combination of comorbidities, medical history, as well as the strengths and components of combination MHT, particularly the gestational component.
Perimenopausal women may need contraception, including COCs. In such circumstances, physicians are faced with such questions as the acceptability of prescribing or continuing to use COCs for menopausal women, as well as when and how to switch from COCs to MHT. Thus, the Forum developed an algorithm for switching from COCs to MHT.

References

  1. https://www.who.int/news-room/fact-sheets/detail/menopause Дата доступу: 10.08.2023
  2. Panay, N., Palacios, S., Davison, S., Baber, R. Women’s perception of the menopause transition: a multinational, prospective, community-based survey, GREM Gynecological and Reproductive Endocrinology & Metabolism (2021); 03/2021: 178–183 doi: 10.53260/GREM.212037
  3. Барна, О.М., Єфіменко, О.О., Косей, Н.В. та співавт. «Медична допомога жінкам у період менопаузи. Клінічна лекція для лікарів загальної практики-сімейних лікарів.» Репродуктивна ендокринологія, № 5(67)/лютий 2023.
  4. Mendoza, N., Ramírez, I., de la Viuda, E., et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group [published online ahead of print, 2022 Aug 30]. Maturitas. 2022; 166: 65-85. doi:10.1016/j.maturitas.2022.08.008
  5. Bild, D.E., Bluemke, D.A., Burke G.L., et al. (November 2002). «Multi-Ethnic Study of Atherosclerosis: objectives and design» (PDF). American Journal of Epidemiology. 156 (9): 871–81. doi: 10.1093/aje/kwf113
  6. Manson, J.E., Chlebowski, R.T., Stefanick, M.L., et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials. JAMA 2013; 310: 1353–68
  7. Roehm, E. A reappraisal of Women’s Health Initiative Estrogen-Alone Trial: long-term outcomes in women 50–59 years of age. Obstet Gynecol Int 2015; 2015: 713295
  8. Nappi et al., “Menopausal transition: a golden age to prevent cardiovascular disease” January 21, 2021 https://doi.org/10.1016/S2213–8587(21)00018–8
  9. Lambrinoudaki, I., Armeni, E., Goulis, D., et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022; 163: 1–14. doi:10.1016/j.maturitas.2022.04.008
  10. Slopiena, R., et al. Menopause and diabetes: EMAS clinical guide. Maturitas 117 (2018) 6–10
  11. Уніфікований клінічний протокол первинної, вторинної (спеціалізованої), третинної (високоспеціалізованої) медичної допомоги (УКПМД) «Менопаузальні порушення та інші розлади в перименопаузальному період» https://www.dec.gov.ua/mtd/menopauzalni-porushennya-ta-inshi-rozlady-v-perymenopauzalnomu-periodi/ дата доступу 07.07.2022
  12. Yang, Z., Hu, Y., Zhang, J., et al. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrinol. 2017 Feb; 33(2): 87–92.
  13. Gompel. A., Plu-Bureau, G. Progesterone, progestins and the breast in menopause treatment. Climacteric. 2018 Aug; 21(4): 326–332.
  14. Vinogradova, Y., Coupland, C., Hippisley-Cox, J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases, Br. Med. J. 364 (2019) k4810.
  15. Lyytinen, H., et al. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009; 113: 65–73; figures were developed de novo using data from associated references; copyright permissions not required
  16. Chlebowski, R.T., Anderson, G.L., Aragaki, A.K., et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA. 2020 Jul 28; 324(4): 369–380. doi: 10.1001/jama.2020.9482. PMID: 32721007; PMCID: PMC7388026.
  17. Franke, Н.R. Vermes 1. Differential effects of progestogens оп breast cancer cell lines. Maturitas. 2003; 46 Suppl 1: S55–S58. doi: 10.1016/j.maturitas.2003.09.019
  18. Fournier, А. et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103–11;
  19. Vinogradova, Y., Coupland, C., Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases BMJ 2020; 371: m3873.
  20. Linton, A., Golobof, A., Shulman, L.P. Contraception for the perimenopausal woman. Climacteric 2016;19(6):526–34
  21. World health organization. Medical eligibility criteria for contraceptive use, 5thedition, 2015. Дата доступу 07.07.2022
  22. www.Who.Int/reproductivehealth/publications/family_ planning Дата доступу 07.07.2022
  23. FSRH Clinical Guideline Combined Hormonal Contraception (January 2019, Amended November 2020). Available at: https://www.fsrh.org/standards-andguidance/ documents/combined-hormonal-contraception/

Downloads

Published

2023-09-29

How to Cite

Editor, R. (2023). Resolution of the IV International Menopause Expert Forum. REPRODUCTIVE ENDOCRINOLOGY, (69), 89–94. https://doi.org/10.18370/2309-4117.2023.69.2-6

Issue

No. 69 (2023)

Section

Management of menopause

License

Copyright (c) 2023 -

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.